Osteoporosis


47% of 90-Day Fracture Readmissions in Women Involve Osteoporosis, Which Tymlos May Help Address

No Image

By: James Pitt  May. 17, 2018

Osteoporosis is a disease that weakens bones and increases the risk of fracture, particularly common in elderly women. First-line treatment is with anti-resorptive drugs like bisphosphonates. A 2017 Lancet study found that patient concerns about bisphosphonates’ side effects limit their use. The American Society for Bone and Mineral Research (ASBMR) recommends that patients on bisphosphonates with low fracture risk take “drug holidays” to decrease their risk of serious side effects.

Read more

Fracture-Related Readmission Rates in Women with Osteoporosis Nearly Double From 30 to 90 Days

No Image

By: James Pitt  May. 07, 2018

Osteoporosis is a disease in which bones lose density over time. It is more common in women than men. According to the Centers for Disease Control, 24.5% of women over 65 have osteoporosis. Bone fractures are an especially important risk of osteoporosis, as elderly people with bone fractures are more likely to die within two years.

Read more

A Study of 30 Day Fracture Readmissions in Iowa Hospitals Highlights Importance of Tymlos

No Image

By: James Pitt  May. 02, 2018

Osteoporosis is a common disease among the Medicare population, which causes bones to lose density and makes them more susceptible to fracture. A 2004 Surgeon General's Report projected that half the women and one quarter of men in the US are likely to have at least one osteoporosis-related fracture in their lifetime.

Read more

Tymlos and the Potential for Osteoporosis Management in Health Systems

No Image

By: James Pitt  Apr. 26, 2018

Dr. Michael Lewiecki of the New Mexico Clinical Research & Osteoporosis Center published a recent study of trends in osteoporosis-related fractures visible in Medicare claims data. Dr. Lewiecki's findings were so alarming Jane Brody of The New York Times referred to them as a "perfect storm" in a February 2018 article.

Read more